Gene Therapy Overview & Updates from Tenaya’s Clinical Trials
Date: December 17, 2025
Time: 6:00pm EDT
Join us for an informative and engaging evening as we explore advancements in gene therapy for inherited cardiomyopathies. This special session will feature Dr. Matt Pollman, Senior Vice President of Clinical Development at Tenaya Therapeutics, who will guide participants through what AAV gene therapies are, how they’re bringing new hope to families affected by inherited heart conditions, and what happens behind the scenes in clinical trials to make sure these treatments are both safe and efficacious.
The first portion of the program will provide an educational overview—perfect for patients, families, and advocates who want to better understand the science and process behind AAV gene therapies and clinical trials. Following this, Dr. Pollman will share insights and results from Tenaya’s recent clinical trials, highlighting what these findings may mean for the future of cardiomyopathy treatment.
The webinar will conclude with a Q&A session, giving attendees the opportunity to submit questions and engage directly with the discussion.
